Journal of Bioequivalence & Bioavailability

Advances in Bioavailability Through Innovative Drug Delivery Systems and Formulation Technologies

Elena Hart ^* Department of Pharmaceutics, Cambridge Institute of Pharmaceutical Sciences, Cambridge, United Kingdom
^*Correspondence: Elena Hart, Department of Pharmaceutics, Cambridge Institute of Pharmaceutical Sciences, Cambridge, United Kingdom, Email:

Received: 12-May-2026 , Manuscript No. JBB-26-31795; Editor assigned: 14-May-2026 , Pre QC No. JBB-26-31795 (PQ); Reviewed: 29-May-2026 , QC No. JBB-26-31795; Revised: 05-Jun-2026 , Manuscript No. JBB-26-31795 (R); Published: 12-Jun-2026 , DOI: 10.35248/0975-0851.26.18.693

Description

Bioavailability remains one of the most important determinants of therapeutic success in pharmaceutical development. It refers to the rate and extent to which an active pharmaceutical ingredient reaches systemic circulation and becomes available at the site of action. Despite significant progress in drug discovery, a considerable proportion of newly developed molecules exhibit poor aqueous solubility, limited permeability, extensive first-pass metabolism, or instability within the gastrointestinal environment. These factors often result in low and variable bioavailability, leading to reduced therapeutic effectiveness and challenges in achieving consistent clinical outcomes. Consequently, substantial research efforts have been directed toward developing innovative technologies and formulation strategies that enhance drug absorption and optimize systemic exposure [1,2].

Recent advances in pharmaceutical sciences have transformed the approach to improving bioavailability. Nanotechnology-based drug delivery systems have emerged as one of the most promising developments in this field. Nanoparticles, nanocrystals, nanosuspensions, and lipid-based nanocarriers provide increased surface area, improved dissolution rates, and enhanced interaction with biological membranes. These systems facilitate better absorption of poorly soluble drugs and can protect active compounds from degradation. Nanocarriers also enable controlled and targeted drug delivery, reducing variability in plasma drug concentrations and improving therapeutic performance. Their ability to modify pharmacokinetic profiles has generated considerable interest for both conventional drugs and newer therapeutic agents [3,4].

Lipid-based formulations have gained widespread acceptance as effective approaches for enhancing oral bioavailability. Self-Emulsifying Drug Delivery Systems (SEDDS), Self-Microemulsifying Drug Delivery Systems (SMEDDS), and lipid nanoparticles improve drug solubilization within the gastrointestinal tract and promote lymphatic transport, thereby reducing the impact of hepatic first-pass metabolism. These systems have demonstrated favorable outcomes for drugs with poor water solubility and have been successfully incorporated into several marketed pharmaceutical products. Advances in excipient technology and formulation optimization have further strengthened the applicability of lipid-based delivery platforms across diverse therapeutic categories [5,6].

Amorphous solid dispersions represent another significant advancement in bioavailability enhancement. Conversion of crystalline drugs into amorphous forms increases their apparent solubility and dissolution rate. The incorporation of polymers helps stabilize the amorphous state and prevents recrystallization during storage and administration. Modern manufacturing techniques such as hot-melt extrusion and spray drying have enabled the large-scale production of stable amorphous solid dispersions with reproducible quality attributes. These technologies have expanded the formulation possibilities for compounds previously considered unsuitable for oral delivery due to poor solubility characteristics [7].

The application of permeability enhancement strategies has also contributed substantially to improving bioavailability. Chemical permeation enhancers, enzyme inhibitors, and absorption modifiers facilitate the transport of drugs across biological barriers. Such approaches are particularly relevant for peptideand protein-based therapeutics, which traditionally exhibit limited oral absorption. Advances in carrier-mediated transport systems and receptor-targeted delivery mechanisms have enabled improved intestinal uptake while maintaining acceptable safety profiles. The growing understanding of membrane transport processes continues to support the development of innovative permeability-enhancing technologies. The emergence of computational modeling and artificial intelligence has further accelerated innovation in bioavailability enhancement. Predictive models assist in understanding drug absorption mechanisms, formulation behavior, and pharmacokinetic performance. Machine learning algorithms can analyze extensive datasets to identify formulation variables associated with improved bioavailability. These technologies support rational formulation design, reduce experimental workload, and facilitate more efficient optimization processes. The integration of computational tools with experimental research is creating new opportunities for personalized and precision-oriented drug delivery systems [8].

Advances in three-dimensional printing technology have introduced additional possibilities for tailoring drug release and absorption characteristics. Customized dosage forms can be designed with specific geometries, release profiles, and drugloading capacities to address individual patient requirements. Such flexibility allows formulation scientists to optimize dissolution and absorption patterns, potentially improving bioavailability while supporting personalized medicine initiatives. Regulatory agencies and pharmaceutical industries increasingly recognize the importance of bioavailability enhancement in improving therapeutic outcomes and reducing variability among patient populations. Improved analytical methods, advanced in vitro–in vivo correlation models, and sophisticated pharmacokinetic assessment techniques have strengthened the evaluation of formulation performance. These developments facilitate the translation of innovative laboratory findings into clinically relevant pharmaceutical products and contribute to more efficient drug development pathways [9,10].

Conclusion

In conclusion, advances in bioavailability enhancement have significantly influenced modern pharmaceutical research and drug development. Innovations such as nanotechnology-based carriers, lipid formulations, amorphous solid dispersions, permeability enhancement techniques, biologic delivery systems, pharmaceutical cocrystals, artificial intelligence-driven formulation design, and three-dimensional printing technologies have expanded the possibilities for improving drug absorption and therapeutic effectiveness. Continued interdisciplinary collaboration among pharmaceutical scientists, clinicians, engineers, and regulatory authorities will support the development of safer, more effective, and patient-centered drug delivery systems capable of addressing longstanding bioavailability challenges.

References

1. Ou YC, Liu L, Tariq B, Wang K, Jindal A, Tang Z, Gao Y, Sahasranaman S. Population pharmacokinetic analysis of the BTK inhibitor zanubrutinib in healthy volunteers and patients with B‐cell malignancies. Clin Transl Sci. 2021;14(2):764-772.
2. CHOU KJ, DONOVAN* MD. Distribution of antihistamines into the CSF following intranasal delivery. Biopharm. Drug Dispos. 1997;18(4):335-346.
3. Ferrer G, Valerio-Pascua F, Alas-Pineda C, Gaitán-Zambrano K, Pavón-Varela DJ, Valerio FR. Intranasal chlorpheniramine for early symptomatic treatment of COVID-19 and the impact on Long-COVID. Cureus. 2025;17(4).
4. Hiep BT, Fernandez C, Khanh V, Hung NK, Thuillier A, Farinotti R, et al. Stereospecific versus nonstereospecific assessments for the bioequivalence of two formulations of racemic chlorpheniramine. Chirality: The Pharmacological, Biological, and Chemical Consequences of Molecular Asymmetry. 2000;12(8):599-605.
5. Huang SM, Chiou WL. Pharmacokinetics and tissue distribution of chlorpheniramine in rabbits after intravenous administration. J Pharmacokinet Biopharm.1981;9(6):711-723.
6. Rickli A, Moning OD, Hoener MC, Liechti ME. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol. 2016;26(8):1327-1337.
7. Becker AM, Klaiber A, Holze F, Istampoulouoglou I, Duthaler U, Varghese N, et al. Ketanserin reverses the acute response to LSD in a randomized, double-blind, placebo-controlled, crossover study in healthy participants. Int J Neuropsychopharmacol. 2023;26(2):97-106.
8. Holze F, Vizeli P, Ley L, Müller F, Dolder P, Stocker M, et al. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology. 2021;46(3):537-544.
9. Holze F, Gasser P, Müller F, Dolder PC, Liechti ME. Lysergic acid diethylamide–assisted therapy in patients with anxiety with and without a life-threatening illness: A randomized, double-blind, placebo-controlled phase II study. Biol Psychiatry. 2023;93(3):215-223.
10. Holford NH, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.Clin pharmacokinet. 1981;6(6):429-453.